A derivative of oleamide potently inhibits the spontaneous metastasis of mouse melanoma BL6 cells

被引:28
作者
Ito, A
Morita, N
Miura, D
Koma, Y
Kataoka, TR
Yamasaki, H
Kitamura, Y
Kita, Y
Nojima, H
机构
[1] Osaka Univ, Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Sch Med, Dept Pathol, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Synth Organ Chem, Suita, Osaka 5650871, Japan
[4] Biosafety Res Ctr Foods Drugs & Pesticides, Shizuoka 4371213, Japan
[5] Kansei Gakuin Univ, Sch Sci & Technol, Sanda, Hyogo 6691337, Japan
关键词
D O I
10.1093/carcin/bgh208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We reported previously that the abnormally augmented expression of connexin 26 (Cx26) is responsible for the enhanced spontaneous metastasis of mouse BL6 melanoma cells, and that the exogenous expression of a dominant negative form of Cx26 inhibits the spontaneous metastasis of BL6. Here we show that daily intraperitoneal (i.p.) injections of oleamide, a sleep-inducing lipid hormone, weakly inhibited the spontaneous metastasis of BL6 cells. To obtain a more effective reagent, 19 oleamide derivatives were chemically synthesized and tested for their ability to inhibit the gap junction-mediated intercellular communications (GJIC) that are formed between HeLa cells by the ectopic expression of Cx26 or Cx43. One of these, denoted metastasis inhibitor-18 (MI-18), inhibited the GJIC formed by Cx26 as well as oleamide but unlike oleamide, which is a non-selective inhibitor of connexin, it did not inhibit the GJIC formed by Cx43. Daily i.p. injections of MI-18 potently blocked the spontaneous metastasis of BL6 cells down to 15% of that in the untreated control mice. MI-18 was safe because even after >7 weeks of daily injections, the survival rate of the mice was 93%. We propose that MI-18 may serve as a novel and clinically important prototype of a potent inhibitor of spontaneous metastasis.
引用
收藏
页码:2015 / 2022
页数:8
相关论文
共 46 条
[1]   v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation [J].
Akagi, T ;
Shishido, T ;
Murata, K ;
Hanafusa, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (13) :7290-7295
[2]   Therapeutic implications of cancer stem cells [J].
Al-Hajj, M ;
Becker, MW ;
Wichal, M ;
Weissman, I ;
Clarke, MF .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (01) :43-47
[3]   Immunohistochemical and ultrastructural study of gap junction proteins connexin26 and 43 in human arachnoid villi and meningeal tumors [J].
Arishima, H ;
Sato, K ;
Kubota, T .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (12) :1048-1055
[4]   Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide [J].
Boger, DL ;
Patterson, JE ;
Guan, XJ ;
Cravatt, BF ;
Lerner, RA ;
Gilula, NB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :4810-4815
[5]   The genetics of malignant melanoma: Lessons from mouse and man [J].
Chin, L .
NATURE REVIEWS CANCER, 2003, 3 (08) :559-570
[6]  
Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO
[7]  
2-C
[8]   Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes [J].
DuflotDancer, A ;
Mesnil, M ;
Yamasaki, H .
ONCOGENE, 1997, 15 (18) :2151-2158
[9]   New functions for the matrix metalloproteinases in cancer progression [J].
Egeblad, M ;
Werb, Z .
NATURE REVIEWS CANCER, 2002, 2 (03) :161-174
[10]   Gap junctions: structure and function (Review) [J].
Evans, WH ;
Martin, PEM .
MOLECULAR MEMBRANE BIOLOGY, 2002, 19 (02) :121-136